{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:11:27Z","timestamp":1788315087079,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To compare infectious risk between JAK inhibitors (JAKis) versus TNF inhibitors (TNFis) among rheumatoid arthritis (RA) patients in Korea.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using 2009\u20132019 Korea National Health Insurance Service database, we conducted a cohort study on RA patients initiating a JAKi or TNFi. The primary outcomes were herpes zoster (HZ), serious bacterial (SBI), and opportunistic infections (OI). Propensity-score fine-stratification (PSS) and weighting were applied to adjust for\u2009&gt;\u200970 baseline covariates. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models comparing JAKi versus TNFi users.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 2963 JAKi initiators PSS-weighted on 5169 TNFi initiators. During a follow-up of 1.16\u00a0years, the most frequent type of infections was HZ with incidence rate (IR) per 100 person-years of 11.54 and 4.88 in JAKi and TNFi users, respectively. The IR of SBI was 1.39 and 1.32, respectively. The OI was rare with a majority being tuberculosis and showed an IR of 0.11 and 0.49 in JAKi and TNFi users, respectively. The PSS-weighted HR (95% CI) for individual types of infections was 2.37 (2.00\u20132.80) for HZ, 1.04 (0.71\u20131.52) for SBI, and 0.25 (0.09\u20130.73) for OI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This population-based cohort study on RA patients treated with JAKi or TNFi in Korea showed an exceptionally high IR of HZ in both treatment groups compared to that from Western countries, with an approximately doubled risk associated with JAKi versus TNFi use. The risk of SBI was comparable, but the risk of OI, particularly tuberculosis, was less among JAKi than TNFi initiators.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03111-w","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T05:01:57Z","timestamp":1690347717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Se Rim","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"3111_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrrheum.2016.200","volume":"13","author":"AI Catrina","year":"2017","unstructured":"Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13:79.","journal-title":"Nat Rev Rheumatol"},{"key":"3111_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1.","journal-title":"Arthritis Rheumatol"},{"key":"3111_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82:95.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53.","journal-title":"Rheumatology (Oxford)"},{"key":"3111_CR8","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275.","journal-title":"JAMA"},{"key":"3111_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3899\/jrheum.100995","volume":"38","author":"EC Keystone","year":"2011","unstructured":"Keystone EC. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol. 2011;38:1552.","journal-title":"J Rheumatol"},{"key":"3111_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther"},{"key":"3111_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","volume":"18","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18:301.","journal-title":"Nat Rev Rheumatol"},{"key":"3111_CR12","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675.","journal-title":"Arthritis Rheumatol"},{"key":"3111_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead079","author":"T Uchida","year":"2023","unstructured":"Uchida T, Iwamoto N, Fukui S, Morimoto S, Aramaki T, Shomura F, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicenter cohort study. Rheumatology (Oxford). 2023. https:\/\/doi.org\/10.1093\/rheumatology\/kead079.","journal-title":"Rheumatology (Oxford)"},{"key":"3111_CR14","first-page":"799","volume":"46","author":"S CheolSeong","year":"2017","unstructured":"CheolSeong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol. 2017;46:799.","journal-title":"Int J Epidemiol"},{"key":"3111_CR15","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/ar3260","volume":"13","author":"SY Kim","year":"2011","unstructured":"Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13:R32.","journal-title":"Arthritis Res Ther"},{"key":"3111_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887.","journal-title":"JAMA"},{"key":"3111_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","volume":"60","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran\u2019s affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60:397.","journal-title":"J Clin Epidemiol"},{"key":"3111_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288.","journal-title":"J Clin Epidemiol"},{"key":"3111_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","volume":"28","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KF. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017;28:249.","journal-title":"Epidemiology"},{"key":"3111_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat-Simul C. 2009;38:1228.","journal-title":"Commun Stat-Simul C"},{"key":"3111_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6646-9","volume-title":"Survival analysis: a self-learning text","author":"DG Kleinbaum","year":"2012","unstructured":"Kleinbaum DG, Klein M. Survival analysis: a self-learning text. 3rd ed. New York: Springer; 2012.","edition":"3"},{"key":"3111_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316.","journal-title":"N Engl J Med"},{"key":"3111_CR23","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020;2:E84.","journal-title":"Lancet Rheumatol"},{"key":"3111_CR24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3:173.","journal-title":"ACR Open Rheumatol"},{"key":"3111_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253.","journal-title":"Ann Rheum Dis"},{"key":"3111_CR27","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960.","journal-title":"Arthritis Rheumatol"},{"key":"3111_CR28","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.4103\/0366-6999.245157","volume":"131","author":"ZG Li","year":"2018","unstructured":"Li ZG, Liu Y, Xu HJ, Chen ZW, Bao CD, Gu JR, et al. Efficacy and safety of tofacitinib in Chinese patients with rheumatoid arthritis. Chin Med J (Engl). 2018;131:2683.","journal-title":"Chin Med J (Engl)"},{"key":"3111_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022504","volume":"99","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Chen YM, Huang WN, Chen HH, Liao TL, Chen JP, et al. Herpes zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan. Medicine (Baltimore). 2020;99: e22504.","journal-title":"Medicine (Baltimore)"},{"key":"3111_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/pds.3602","volume":"23","author":"W Camelo Castillo","year":"2014","unstructured":"Camelo Castillo W, Delaney JA, Sturmer T. The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan. Pharmacoepidemiol Drug Saf. 2014;23:357.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03111-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03111-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03111-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T05:03:55Z","timestamp":1690347835000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03111-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3111"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03111-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the Seoul National University Bundang Hospital approved the study protocol (X-2207\u2013770-901) and waived the need for written patient consent based on de-identified database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable based on no individual person\u2019s data included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}